Gene Therapy MYO-101 Receives FDA’s Orphan Drug Status for LGMD2E Treatment – Muscular Dystrophy News
Muscular Dystrophy News |
Gene Therapy MYO-101 Receives FDA's Orphan Drug Status for LGMD2E Treatment
Muscular Dystrophy News The U.S. Food and Drug Administration (FDA) granted orphan drug status to MYO-101, a gene therapy being developed by Myonexus Therapeutics for the treatment of limb girdle muscular dystrophy type 2E (LGMD2E) . The FDA's orphan drug designation is … |
